Dry Eye Drugs Market 2022 Competitive Insights and Precise Outlook - Allergan, Novartis AG, Bausch Health, Santen Pharma, Takeda, Johnson & Johnson

The research report studies the Dry Eye Drugs market using different methodologies and analyzers to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each place is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The data analysts have used primary and secondary methodologies to consolidate the information in the report.. They have also used the same data to generate the current business scenario. This report also provides an analysis of the impact of the COVID-19 pandemic on Dry Eye Drugs Industry.

The global Dry Eye Drugs market size is USD million in 2022 from USD 8392.4 million in 2021, with a change of % between 2021 and 2022. The global Dry Eye Drugs market size will reach USD 19080 million in 2028, growing at a CAGR of 12.4% over the analysis period.

Top Leading Companies of Global Dry Eye Drugs Market are Allergan, Novartis AG, Bausch Health, Santen Pharma, Takeda, Johnson & Johnson, United Laboratories, Senju Pharmaceutical, Jianfeng Group, Eusan GMBH and others.

Get Free Sample Copy of this Report:

https://www.marketinsightsreports.com/reports/01044632620/global-dry-eye-drugs-market-growth-2022-2028/inquiry?Mode=PD

Regional Analysis:

Global Dry Eye Drugs key players include Novartis AG, Valeant Pharmaceuticals, Allergan, Johnson & Johnson, Santen Pharma, etc. Global top five manufacturers hold a share about 75%.

North America is the largest market, with a share about 40%, followed by Asia-Pacific, and Europe, both have a share about 40 percent.

In terms of product, Artificial Tears is the largest segment, with a share over 85%. And in terms of application, the largest application is Hospital, followed by Drug Stores, Online Pharmacies.

Industry News and Updates:

Novartis to Acquire Dry Eye Drug Xiidra in Deal Worth Up to $5.3 Billion

In one of the largest ophthalmic drug deals to date, Novartis has agreed to acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda Pharmaceutical in a deal worth up to $5.3 billion.

Under terms of the deal, Novartis will pay $3.4 billion upfront, plus potential milestone payments of up to $1.9 billion. Novartis will be taking on approximately 400 employees associated with the product.

The deal is expected to close in the second half of 2019.

Xiidra is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The FDA approved Xiidra in 2016, becoming just the second drug approved in the United States for dry eye disease, joining Allergan’s Restasis (cyclosporine ophthalmic emulsion) 0.05%, which was approved in 2003.

By Types:

Artificial Tears

Anti-inflammatory Drugs

Other

By Application(Dry Eye Drugs)

Hospital

Drug Stores

Online Pharmacies         

The regions are further sub-divided into:

-North America  – US, Canada, and Mexico
-Europe  – UK, Germany, France, Italy, Russia, Spain & Rest of Europe
-Asia-Pacific  – China, India, Japan, South Korea, Australia & Rest of APAC
-Latin America  – Brazil, Argentina, Peru, Chile & Rest of Latin America
-Middle East and Africa – Saudi Arabia, UAE, Israel, South Africa

Integrated Dry Eye Drugs Market Report Highlights:

-Detailed overview of the parent market
-Changing market dynamics in the industry
-In-depth market segmentation
-Historical, current and projected market size in terms of volume and value
-Recent industry trends and developments
-Competitive landscape
-Strategies of key players and products offered
-Potential and niche segments, geographical regions exhibiting promising growth
-A neutral perspective on market performance

Browse Full Report for TOC and Description:

https://www.marketinsightsreports.com/reports/01044632620/global-dry-eye-drugs-market-growth-2022-2028?Mode=PD

Key Questions Answered in the Global Dry Eye Drugs Industry Report

What will be the Dry Eye Drugs market size?
What are the new opportunities?
What is the market share?
What are targeted audiences?
Which are the top players in Dry Eye Drugs market?
How the competition goes in the future?
Which are the leading countries?
What are the challenges in future?

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing. Further, it also allows you to do valuable competitor research to get inspiration for marketing the products. When it comes to satisfaction, it is necessary to get definitive idea about what is exactly going in the market. This report exactly provides overall market scenario.

Buy this Report at:

https://www.marketinsightsreports.com/report/purchase/01044632620?mode=su?Mode=PD

Report Customization:

Global Dry Eye Drugs Market, report can be customized according to your business requirements as we recognize what our clients want, we have extended 15% customization at no additional cost to all our clients for any of our syndicated reports.

In addition to customization of our reports, we also offer fully tailored research solutions to our clients in all industries we track.

Our research and insights help our clients in identifying compatible business partners.

Contact US:
Irfan Tamboli (Head of Sales) : Market Insights Reports
Phone: + 1704 266 3234 | Mob: +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.